肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

梁利梅; 王才智; 刘淑玉

肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

1.
蚌埠医学院第一附属医院妇产科, 安徽蚌埠233004

作者简介: 梁利梅(1982-) ,女,住院医师

基金项目:

Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer

1.
Department of Obstetrics and Gynecology,The First Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233004,China

摘要: 目的:检测人肿瘤坏死因子相关凋亡诱导配体(TNF-related aPoPtosis-inducing ligand,TRAIL)的诱骗受体2(DcR2)、死亡受体5(DR5)在子宫内膜癌的表达及其临床意义。方法:采用免疫组织化学SP法检测52例子宫内膜癌组织、20例不典型增生子宫内膜组织、23例正常子宫内膜组织中DR5、DcR2阳性表达水平。并对子宫内膜癌患者的手术病理分析、肿瘤分化程度、组织类型、肌层浸润等临床病理因素进行分析。结果:DcR2在正常子宫内膜组织中的表达高于子宫内膜癌组织(P0.01);DR5在正常子宫内膜、不典型增生子宫内膜和子宫内膜癌组织中的表达呈递增趋势,两两比较差异均有统计学意义(P0.01)。结论:子宫内膜癌细胞由于高表达DR5和低表达DcR2而易被TRAIL诱导凋亡,这一结果为临床治疗子宫内膜癌提供可能实验依据。
- 子宫肿瘤 /
- 肿瘤坏死因子相关诱导配体 /
- 诱骗受体2 /
- 死亡受体5 /
- 细胞凋亡 /
- 免疫组织化学
Abstract: Objective: To investgate the expression and clinical significance of the deathreceptor 5(DR 5) and decoyreceptor 2(DcR 2) of TNF-related apoptosis-inducing ligand (TRAIL) in endometrial cancer. Methods: The expressions of DR5 and DcR2 of endometrium tissues from 52 cases with endometrial cancer,20 cases with atypical endometrium hyperplasia and 23 cases normal endometrium tissue were detected by immunohistochemistry. The pathological grade of surgery, tumor differentiation degree, tissue type, muscular layer infiltration and clinical pathological factors of endometrial cancer were analyzed. Results: The expressions of DcR2 of normal endometrium tissue were higher than that of endometrial cancer tissue (P ＜ 0. 01 ) . The expressions of DR5 of normal endometrium,atypical endometrium hyperplasia and endometrial cancer tissue showed increasing trend,the Results of multiple comparison had statistically significant (P ＜ 0. 01) . Conclusions: Endometrium carcinoma cells can be easily induced apoptosis by TRAIL with high expression of DR5 and low expression of DcR2,which can provide a basis for treating endometrium carcinoma.
- uterine tumor /
- TNF-related apoptosis-inducing ligand /
- decoyreceptor 2 /
- deathreceptor 5 /
- cell apoptosis /
- immunohistochemistry

[1]	曹泽毅. 中华妇产科学[M]. 2 版. 北京: 人民卫生出版社, 2005: 2120-2128.
[2] Wiley SR,Schooley K,Smolak PL,et al. Identification and characterization of New member of the TNF family that induces apoptosis[J]. Immunity, 1995,3 (6):673-682.
[3] Gura T. How kills cancer cell,but normal cells[J]. Science, 1999, 227(5381):768-777.
[4] Hideo Y,Kazuyoshi T,Yoshihiro H, et al. TRAIL and its receptors as targets for cancer therapy[J]. Cancer Sci,2004,95 (10 ):777-783.
[5] Galligan LG,Longley DB,Mcewan M,et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of P53, TRAILreceptors,and c-FLIP[J]. Mol Cancer Ther,2005,4 (12):2026-2036.
[6] Wagner KW,Punnoose EA, Januario T, et al. Death-receptor Oglycosylation controls tumor-cell sensitivity to the proapoptotic ligand ApO2 L /TRAIL[J]. Nat Med, 2007,1 3(9):1070-1077.
[7] Pollack IF,Erff M,Ashkenazi A. Direct stimulation of apoptosis signaling by soluble ApO2 L /tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells [J]. Clin Cancer Res, 2001,7 (5):1362-1369.
[8] Liu XS,Zhu Y,Han WN, et al. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4,DR5,DcRl and DcR2[J]. Hybrid Hybridomics,2003,22 (2):121-123.
[9] Krieg A,Krieg T,Wenzel M, et al. TRAIL-beta and TRAIL-gama. two novel splice variants of the human TNF-related apoptosis inducing ligand (TRAIL) without apoptosis potential [J]. Br J Cancer,2003,8 8(6):918-927.
[10] 李榕,姖秋和,刘雪松,等. 子宫内膜癌中TRAIL 诱骗受体的表达研究[J]. 医学研究生学报, 2003, 16(7):489-490.
[11] Arts HJ, Jong S,Hollema H,et al. Chemotherapy induces death receptors 5 inepithellial ovarian carcinoma[J]. Gynecol Oncol, 2004, 92(3):794-800.
[12] 公伟,李占元,曾庆东,等. 肿瘤坏死因子相关凋亡诱导配体联合化疗药物杀伤胰腺癌细胞的研究[J]. 中华肝胆外科杂志,2 006, 12(2):111-113.
[13] 胡建昆,杨昆,李春梅,等. TRAIL 及其受体在直肠癌组织中的表达[J]. 中国普外基础与临床杂志,2009,16 (2):137-140.
[14] Greco FA,Bonomi P,Crawford J,et al. Phase 2 study of mapatumumab,a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer[J]. Lung Cancer,2008,61 (1):82-90.
[15] Kelley RF,Totpal K,Lindstrom SH,et al. Receptor-selective mutants of Apoptosis-inducing Ligand2 /tumor necorsis factorrelated apoptosis-inducing ligand reveal a greater contribution of death receptor 5 than DR4 to apoptosis signaling[J]. Biol Chem, 2005, 280(3):2205-2212.
[16] Vander S,Tur V,Szegezdi E,et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor[J]. PNAS,2006,1 03 (23):8634-8639.
[17] Baritaki S,Huerta-Yepez S,Sakai T,et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: upregulation of DR5 and inhibition of Yin Yang 1[J]. Mol Cancer Ther,2007,6 (4):1387-1395.
[18] Adams C,Totpal K,Lawrence D, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5[J]. Cell Death Differ,2008, 15(4):751-761.
[19] 主该侠,曲群,陈青娟,等. 子宫内膜癌中TRAIL 受体DR5, DcR1 及P-gp 的表达及意义[J]. 山西医科大学学报,2 006,3 7 (8):800-803.
[20] Frank S,Kohler U,Schackert G, et al. Expression of TRAIL and its receptors in human brain tumors [J]. Biochem Biophy Res Commun,1999,2 57(3):454-459.
[21] Jin H,Yang R,Fong S, et al. ApO2 ligand /tumor necrosis factor related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improvesurvival[J]. Cancer Res,2004,6 4(14):4900-4905.

[1]	郭苏阳 , 李群 . 雌激素受体亚型表达与子宫内膜癌预后的关系. 蚌埠医学院学报, 2009, 34(10): 895-897.
[2]	蔡兆根 , 谢群 , 郭冰沁 . 子宫上皮样滋养细胞肿瘤1例并文献复习. 蚌埠医学院学报, 2010, 35(10): 996-999.
[3]	王才智 , 吕合作 , 席玉玲 , 晋茂生 , 何玉 , 郭才 , 凌斌 . TRAIL受体在子宫内膜癌细胞株的表达. 蚌埠医学院学报, 2008, 33(1): 12-14.
[4]	刘燕 , 周长春 , 田强 , 孙阿妮 , 丰义宽 , 李国庆 . 结肠癌组织中p53凋亡刺激蛋白家族表达水平及其与临床病理学特征的相关性研究. 蚌埠医学院学报, 2016, 41(12): 1594-1596. doi: 10.13898/j.cnki.issn.1000-2200.2016.12.017
[5]	胡应光 , 谢闵 , 赵剑 . 乳腺癌HER-2基因显色原位杂交与免疫组织化学检测对比研究. 蚌埠医学院学报, 2009, 34(11): 959-961.
[6]	杜丹丽 , 郭才 , 谭玉林 . 滋养细胞肿瘤子宫动脉灌注化疗13例分析. 蚌埠医学院学报, 2005, 30(6): 498-499.
[7]	陆洁雅 , 卫德强 , 唐燕 , 许琦 . FGD5-AS1/miR-519d-3p轴调控高糖诱导的肾小管上皮细胞HK-2炎症因子表达和细胞凋亡. 蚌埠医学院学报, 2023, 48(3): 290-295. doi: 10.13898/j.cnki.issn.1000-2200.2023.03.003
[8]	刘杜先 , 刘兰侠 , 张杰东 . GPC-3、CD10、CD147、CD138免疫组织化学联合检测对于高分化肝细胞癌与异型增生的鉴别诊断价值. 蚌埠医学院学报, 2019, 44(12): 1660-1663. doi: 10.13898/j.cnki.issn.1000-2200.2019.12.022
[9]	耿建 , 荣梅生 , 周继红 . 趋化因子受体CXCR7在肝细胞性肝癌组织中的表达及其意义. 蚌埠医学院学报, 2012, 36(5): 523-524,528.
[10]	陈正徐 , 章尧 , 陈昌杰 . 三氧化二砷诱导肿瘤细胞凋亡的机制及信号传导. 蚌埠医学院学报, 2008, 33(1): 116-118.
[11]	牛多山 , 葛霞 . claudin-1、claudin-4在子宫内膜癌的表达及其意义. 蚌埠医学院学报, 2008, 33(5): 515-517,632.
[12]	高绪锋 , 陈昌杰 , 王东萍 , 章尧 . bcl-2和bax在三氧化二砷诱导HL-60细胞凋亡过程中的变化. 蚌埠医学院学报, 2009, 34(1): 9-11.
[13]	梁猛 . XIAP基因对TNF-α诱导的鼻咽癌细胞凋亡及VEGF和COX-2表达的机制研究. 蚌埠医学院学报, 2022, 47(3): 284-288. doi: 10.13898/j.cnki.issn.1000-2200.2022.03.002
[14]	杨振中 . 子宫内膜间质肿瘤病理进展. 蚌埠医学院学报, 2009, 34(8): 750-753.
[15]	卢珍 , 武世伍 . 含WW结构域的氧化还原酶在子宫颈癌中的表达及其临床意义. 蚌埠医学院学报, 2015, 40(9): 1222-1223. doi: 10.13898/j.cnki.issn.1000-2200.2015.09.029
[16]	郭苏阳 , 颜士杰 , 李群 , 李胜泽 . 缺氧诱导因子-1和碳酸酐酶-9在子宫颈鳞状细胞癌组织中的表达及其临床意义. 蚌埠医学院学报, 2013, 37(2): 142-145.
[17]	张燕 , 申庆文 . 重度子痫前期患者血清可溶性血管内皮生长因子受体1及胎盘组织中胎盘生长因子的表达及意义. 蚌埠医学院学报, 2010, 35(12): 1238-1239,1242.
[18]	瓮生彬 , 张建波 , 张淑艳 , 郑超 , 白杰 , 徐德龙 . 血管内皮生长因子、雌激素受体在甲状腺乳头状癌和甲状腺滤泡状腺瘤组织中的表达及其意义. 蚌埠医学院学报, 2010, 35(1): 37-39.
[19]	陶新全 , 王明明 . ¹⁸氟-脱氧葡萄糖诱导Lewis肺癌细胞凋亡的实验研究. 蚌埠医学院学报, 2009, 34(10): 865-867.
[20]	王浜 , 何玉 . Sox4和E-cadherin在子宫颈鳞状细胞癌中的表达及临床意义. 蚌埠医学院学报, 2018, 43(4): 467-470. doi: 10.13898/j.cnki.issn.1000-2200.2018.04.012

点击查看大图

计量

文章访问数: 3653
HTML全文浏览量: 462
PDF下载量: 119
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

作者简介: 梁利梅(1982-) ,女,住院医师

Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer

计量

肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

作者简介: 梁利梅(1982-) ,女,住院医师

English Abstract

Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer

全文HTML

目录

留言板

肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

作者简介: 梁利梅(1982-) ,女,住院医师

Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer

计量

出版历程

肿瘤坏死因子相关凋亡诱导配体受体、死亡受体5及诱骗受体2在子宫内膜癌中的表达及其临床意义

作者简介: 梁利梅(1982-) ,女,住院医师

English Abstract

Expression and clinical significance of the deathreceptor 5 and decoyreceptor 2 of TNF-related apoptosis-inducing ligand in endometrial cancer

全文HTML

目录